Robert Emery, MD
Urology · Batesville, ARNPI 1619945714
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $18,312 of the $23,134 with a category attached, or 79.2%. Ozark Cryosurgery, LLC accounts for 79.2% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $8,912 and has fallen 91.2% since, to $780 in 2025.
Across 212 payments — averaging $109.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ozark Cryosurgery, LLC$18K
- Procept Biorobotics Corporation$733
- Astellas Pharma US Inc$560
- Boston Scientific$544
- Sumitomo Pharma America, Inc.$229
- Organogenesis Inc.$226
- plus $3K from 35 others
What the payments were for
- Travel & lodging$3722%
- Food & beverage$4,45019%
- Ownership interest$18,31279%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ozark Cryosurgery, LLC | 3 | $18,312 |
| Procept Biorobotics Corporation | 13 | $733 |
| Astellas Pharma US Inc | 34 | $560 |
| Boston Scientific | 11 | $544 |
| Sumitomo Pharma America, Inc. | 11 | $229 |
| Organogenesis Inc. | 10 | $226 |
| AbbVie(2 entities) | 14 | $225 |
| Coloplast | 8 | $208 |
| Pfizer | 14 | $193 |
| Axonics, Inc. | 8 | $192 |
| Bayer | 10 | $188 |
| Urogen Pharma, Inc. | 7 | $170 |
| Johnson & Johnson | 10 | $165 |
| Teleflex LLC | 4 | $153 |
| Myovant Sciences Inc. | 8 | $135 |
| Tolmar Pharmaceuticals, Inc. | 7 | $119 |
| Cook Medical LLC | 3 | $90 |
| Medtronic(2 entities) | 5 | $71 |
| BK Medical Holding Company Inc. | 1 | $58 |
| Olympus America Inc. | 3 | $57 |
| Tolmar, Inc. | 2 | $47 |
| Blue Earth Diagnostics | 3 | $41 |
| KCI USA, Inc. | 3 | $39 |
| Progenics Pharmaceuticals, Inc. | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| TELA Bio, Inc. | 1 | $31 |
| Neotract Inc. | 1 | $27 |
| 180 Medical, Inc. | 1 | $27 |
| Biogen | 1 | $25 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Conmed Corporation | 1 | $18 |
| Acera Surgical, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Stryker | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Innocoll Pharmaceuticals Limited | 1 | $12 |
| Amgen | 1 | $12 |
| Acell, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$343
- Axonics$136
How this compares
$23,134 in reported general payments places this provider in the 80th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 27 | $396,699 |
| MyrbetriqMirabegron | 116 | $70,450 |
| GemtesaVibegron | 12 | $7,874 |
| Tamsulosin Hcl | 735 | $7,550 |
| Finasteride | 195 | $1,575 |
| Solifenacin Succinate | 43 | $1,094 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $509 |
| Cephalexin | 110 | $476 |
| Oxybutynin Chloride | 43 | $387 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 75 | $366 |
| Doxazosin Mesylate | 34 | $304 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $262 |
| Levofloxacin | 54 | $159 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $119 |
| Ciprofloxacin Hcl | 15 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $560 | $467,149143 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $229 | $7,87412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 urology providers in Arkansas.
Other urology in Batesville
- Hunter BrownBatesville$23K
- Joel UbedaBatesville$1K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.